General Information of Drug (ID: DM56T1P)

Drug Name
Heterocyclic derivative 26 Drug Info
Synonyms PMID27410995-Compound-Figure3h
Cross-matching ID
TTD Drug ID
DM56T1P

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Preclinical Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
1,6-diazanaphthalenes and pyrido[2,3-d] pyrimidine derivative 1 DMUQ9CF N. A. N. A. Patented [1]
1,6-diazanaphthalenes and pyrido[2,3-d] pyrimidine derivative 2 DMPZ0U8 N. A. N. A. Patented [1]
Pyrrolo[2,3-d]pyrimidine derivative 1 DMYUEA6 N. A. N. A. Patented [1]
Pyrrolo[2,3-d]pyrimidine derivative 2 DMJFYK1 N. A. N. A. Patented [1]
BI-D1870 DMK3SAF Chronic lymphocytic leukaemia 2A82.0 Preclinical [2]
PMID19364658C33 DMSE1C3 Discovery agent N.A. Investigative [3]
GSK-1838705A DM4HLK3 Discovery agent N.A. Investigative [4]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Ribosomal protein S6 kinase alpha-1 (RSK1) TTIXKA4 KS6A1_HUMAN Inhibitor [1]

References

1 Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78.
2 BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem J. 2007 Jan 1;401(1):29-38.
3 Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem. 2009 May 1;17(9):3342-51.
4 GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol Cancer Ther. 2009 Oct;8(10):2811-20.